Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage for it.
When the collaboration between Novo Nordisk and Hims & Hers was announced in April, Wegovy was made available on Hims through Novo Nordisk's NovoCare Pharmacy for a discounted price of $499 per month, in addition to Hims' monthly subscription fee. Hims has also continued to sell "personalized" doses of compounded semaglutide -- the main active ingredient in Wegovy -- for $165 per month, according to its website.
Wegovy is approved by the U.S. Food and Drug Administration for weight loss in people with obesity or who are overweight with additional risks for cardiovascular disease.
In explaining the decision to end the collaboration, Novo Nordisk alleged that Hims & Hers' has continued to offer compounded versions of Wegovy "under the false guise of 'personalization.'"
"Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy," Dave Moore, Novo Nordisk's executive vice president of U.S. Operations, said in a news release Monday. "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety -- and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action."
Wegovy to be sold on Hims, Ro and LifeMD for reduced price
Hims & Hers' CEO Andrew Dudum said in a statement shared on X that the platform intends to continue to provide Wegovy for patients.
"We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients. We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice," Dudum said. "We take our role of protecting the ability of providers and patients to control individual treatment decisions extremely seriously, and will not compromise the integrity of our platform to appease a third party or preserve a collaboration. The health and wellness of individuals always comes first.
He continued, "We will continue to offer access to a range of treatments, including Wegovy, to ensure providers can serve the individual needs of patients."
Hims & Hers did not immediately reply to ABC News' request for further clarification about Wegovy remaining available on the platform.
A spokesperson for Novo Nordisk told ABC News they have no additional comment.
Compound drugs are copies of FDA-approved medications. They are made by licensed pharmacies, but not approved or inspected by the FDA.
Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when a patient can't take a version of a drug made by a pharmaceutical company and they need an alternative.
In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity.
The FDA has declared the shortages as "resolved," removing the drugs from its shortage list.
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
Last week, a federal judge in Texas upheld the FDA's decision to remove semaglutide from the shortage list, blocking compounding pharmacies from making copies of Wegovy and Ozempic, according to court documents.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
America's housing is pulling further out of reach, report finds
Harvard researchers document the increasing costs and challenges of finding housing for both renters and owners A new report from one of the nation's premiere housing research groups confirms what many of us already know: residential real estate is pulling further away from ordinary Americans, becoming more expensive, less attainable, and increasingly stymying efforts to make a market that works for everyone. The State of the Nation's Housing 2025, from the Joint Center for Housing Studies of Harvard University, lays out the numbers in stark detail. What those numbers actually look like can be seen in the charts below. Do young people complain too much about the high cost of housing? Americans have always stretched to buy their homes, and many older people remember when mortgage rates were in the double digits. But by one measure, conditions have rarely been this challenging. The median-priced home was five times greater than the median household income in 2024, according to the report, 'significantly' above the ratio of three times, which has traditionally been a rough rule of thumb about what's affordable. Going back to 1990, the only other period in which the ratio was this high was 2005, at the height of the subprime bubble. More: OK, boomer: Why older Americans have the upper hand in the housing market Of course, one of the oldest truths about housing is that all real estate is local. Even now, there are plenty of places where dollars stretch further. Consider: a borrower would need an income of $595,389 to afford the median-priced home in the San Jose, California metro area, which is just over $2 million. But you could pick up a typical home in Waterloo-Cedar Falls, Iowa, or Charleston, West Virginia, for one-tenth that amount. Read more: Rents remain far above pre-COVID levels. Use this tool to check prices in your area Finally, it's worth remembering that it's not just homes for purchase that are pulling out of reach. The rent is still too darn high for far too many Americans. There are some policies that may help alleviate high costs, Whitney Airgood-Obrycki, a senior research associate at the Harvard Joint Center for Housing Studies, told USA TODAY. Zoning tends to be the first point of friction. Allowing multifamily housing in places that are zoned for single family only can ease that. But the reform needs to go beyond that change. "We can make building as easy as possible," Airgood-Obrycki said, "but for people at the bottom of the market who are severely rent burdened and have been over time, new construction really isn't going to solve their problem." Read next: Homeowners have nearly 40x the wealth of renters. But what's causing the wealth gap? That is where federal and state subsidies, in the form of vouchers and public housing, can be helpful, Airgood-Obrycki added. The Harvard report reminds readers that 'cost burdens' have a human toll: in January 2024, 771,480 people were homeless, up a whopping 33% since January 2020.
Business Upturn
2 hours ago
- Business Upturn
TISSIUM Receives FDA De Novo Authorization for COAPTIUM® CONNECT in Atraumatic Sutureless Peripheral Nerve Repair
This regulatory milestone marks TISSIUM's entry into the U.S. market and establishes the foundation of the TISSIUM polymer platform for atraumatic tissue repair Paris, France, Cambridge, USA, June 24, 2025 – TISSIUM, a MedTech company pioneering biomorphic programmable polymers for tissue reconstruction, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing authorization for COAPTIUM® CONNECT with TISSIUM Light, a first-of-its-kind atraumatic sutureless solution for peripheral nerve repair. This authorization represents a pivotal regulatory milestone for TISSIUM, further validating its biopolymer platform and enabling U.S. commercialization of its first product. COAPTIUM® CONNECT is now the only FDA-authorized system designed for atraumatic sutureless nerve coaptation. Christophe Bancel, Co-Founder and CEO of TISSIUM said: 'This FDA marketing authorization validates over a decade of scientific and clinical commitment to developing next-generation solutions in tissue reconstruction. COAPTIUM® CONNECT is the first demonstration of the transformative potential of our polymer platform and an important step in making atraumatic tissue repair available to patients.' Peripheral nerve injuries affect hundreds of thousands of patients annually and are typically repaired using microsurgical sutures. However, this approach presents limitations—including technical complexity, risk of additional trauma, and variable outcomes. COAPTIUM® CONNECT addresses these challenges by offering a reproducible, atraumatic sutureless alternative that preserves nerve integrity and simplifies the coaptation process1. In a recent clinical study on 12 patients with digital nerve injuries, COAPTIUM® CONNECT achieved 100% procedural success, defined as successful atraumatic sutureless coaptation using the polymer-assisted coaptation device, with all patients regaining full flexion and extension of the injured digit and reporting no pain 12 months after the procedure1. TISSIUM plans to initiate commercial rollout of COAPTIUM® CONNECT in the coming months. The COAPTIUM® CONNECT System leverages TISSIUM's unique biopolymer platform, invented by Maria Pereira, Jeffrey Karp and Robert Langer at the MIT and Brigham & Women's Hospital, using its bioresorbable light-activated surgical polymer and its 3D-printed polymer chamber. Maria Pereira, Co-Founder and Chief Innovation Officer, said: 'This first product illustrates the technical versatility and the potential of the TISSIUM polymer platform, not only in peripheral nerve repair where other solutions are currently under development, but also in other surgical applications, such as atraumatic hernia repair and cardiovascular sealing.' *** About TISSIUM TISSIUM is a clinical and commercial stage MedTech company based in Paris, France, Cambridge, USA, and with a manufacturing site in Roncq, France. The company is pioneering a proprietary platform of fully biosynthetic, biomorphic, programmable, elastomeric polymers designed to address critical unmet needs in atraumatic tissue repair and tissue reconstruction. TISSIUM's diversified pipeline includes seven products across three core verticals: sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. Each solution is designed to optimize tissue repair through controlled and consistent procedures with specialized delivery and activation devices to maximize the performance and usability of its products. Founded in 2013, TISSIUM is built on breakthrough research and intellectual property originating from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women's Hospital). For more information, please visit and follow us on LinkedIn: TISSIUM. *** Contacts Investor relationsRomain Attard – Chief Financial Officer [email protected]
Business Insider
2 hours ago
- Business Insider
Hims & Hers stock plunges after Novo Nordisk ends its brief partnership
Hims & Hers stock plunged 35% on Monday after its collaboration with Novo Nordisk came to a halt. The Danish pharmaceutical giant said it was ending the partnership because Hims is selling and promoting a cheaper copycat of Novo's blockbuster weight loss drug, Wegovy. "Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk," Novo said in a statement on Monday. Novo added that according to its investigation, telehealth companies that compound semaglutide drugs use ingredients "manufactured by foreign suppliers in China." Novo said that Hims would no longer have direct access to Wegovy. Novo's stock closed more than 5% lower on Monday. In a statement on X on Monday, Hims' CEO Andrew Dudum said Novo was being anti-competitive and that Hims will continue to provide a range of treatments, including Wegovy. "In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," he wrote. "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice." Hims' stock has been on a roller coaster this year, with shares dropping and jumping sharply on new developments in the weight loss drug industry. At the end of April, Hims stock surged 20% after Novo announced a long-term collaboration with Hims to make obesity treatments accessible on the Hims platform. The announcement came just months after Hims' CEO said that the company would no longer sell compounded versions of Novo's weight loss drugs. Instead, it would sell "personalized" dosages of Wegovy under rules allowing it for clinical reasons such as decreased side effects. The company's stock fell over 19% following Dudum's remarks on Novo. The company was allowed to make legal copies of Novo's weight loss and diabetes drugs Ozempic and Wegovy during a shortage that began in 2022. In February, the US Food and Drug Administration removed semaglutide injection products from its shortage list and gave compounders 60-90 days to stop making copies. Hims is up 74% this year. Novo is down 19% this year on worries that the company is rapidly losing market share to American pharmaceutical rival Eli Lilly.
